Satoshi Ikeda, Takashi Ogura, Terufumi Kato, Hirotsugu Kenmotsu, Yoko Agemi, Takaaki Tokito, Kentaro Ito, Kohsuke Isomoto, Yuichi Takiguchi, Yasuto Yoneshima, Toshihide Yokoyama, Toshiyuki Harada, Shigeru Tanzawa, Nobuaki Kobayashi, Tae Iwasawa, Toshihiro Misumi, Hiroaki Okamoto
Rationale : A fatal acute exacerbation (AE) occasionally develops during chemotherapy for small-cell lung cancer (SCLC) with comorbid idiopathic pulmonary fibrosis (IPF). Objectives : This study aimed to assess the safety and efficacy of carboplatin, etoposide, and nintedanib combination therapy for unresectable SCLC with comorbid IPF. Methods : The NEXT-SHIP study is a multicenter, single-arm, phase 2 trial for unresectable SCLC with IPF (registry number: jRCTs031190119). The patients received carboplatin, etoposide, and nintedanib (150 mg BID)...
February 16, 2024: Annals of the American Thoracic Society